



Evaluation of malignant intraductal papillary mucinous neoplasms 
of the pancreas on computed tomography and magnetic resonance 
imaging
Nieun Seo,1 Jae Ho Byun2,*
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Preoperative cross-sectional imaging, such as computed tomography and magnetic resonance imaging, plays a key role in differentiating between 
benign and malignant intraductal papillary mucinous neoplasms. This article reviews the imaging features associated with malignant intraductal 
papillary mucinous neoplasm, as well as the recent studies validating the 2012 international consensus guidelines. This review also compared the 
diagnostic performance of computed tomography and magnetic resonance imaging in differentiating malignant from benign intraductal papillary 
mucinous neoplasms.
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Introduction
Cystic lesions of the pancreas are increasingly being detected, 
due to the more widespread use of and advances in cross-section-
al imaging and the increased frequency of health examinations. 
Although the exact incidence of intraductal papillary mucinous 
neoplasms (IPMNs) of the pancreas has not been determined, 
IPMNs have been estimated to account for approximately 20% to 
50% of all pancreatic cystic neoplasms.1,2 IPMNs have been clas-
sified as branch duct (BD) type, main duct (MD) type, and com-
bined or mixed type based on imaging findings and/or histology.3 
Computed tomography (CT) and magnetic resonance imaging 
(MRI), along with magnetic resonance cholangiopancreatography 
(MRCP), are the most useful radiologic methods for detecting 
IPMNs. Moreover, these imaging modalities are useful in distin-
guishing BD-IPMNs from other cystic lesions by showing multi-
plicity and a connection to the main pancreatic duct (MPD). As 
the management of IPMNs depends on their malignant potential, 
it is essential to accurately predict the risk of malignancy of each 
tumor on preoperative imaging.
Radiologic Findings of Pancreatic IPMNs
BD-IPMNs have been found to manifest as either grape-like 
clusters of cysts or cysts without dilatation of the MPD (Fig. 1).4 
Although BD-IPMNs may be located anywhere, the pancreatic 
head, especially the uncinate process is the most common site.4 
Of patients with BD-IPMN, 39%–64% have been found to show 
multiplicity.5,6 Identification of the communication between the 
cystic lesion and the MPD is one of the most reliable findings for 
diagnosis of BD-IPMN. MRI with MRCP has shown better diag-
nostic performance than CT in differentiating IPMNs from other 
pancreatic cystic lesions by showing the ductal communication of 
cystic lesions with MPD.7–9
MD-IPMNs appear as dilated and tortuous MPDs, with the 
dilatation extending into the secondary branches that sometimes 
appear cystic (Fig. 2).4 MD-IPMNs show a much higher malignant 
potential than BD-IPMNs (40%–95% vs 12%–62%).7,10–12 Accord-
ing to recent International Association of Pancreatology guide-
lines,7 the threshold of MPD for characterization of MD-IPMN 
has been lowered to > 5 mm in the absence of other causes of 
obstruction. MPD dilatation of 5–9 mm is considered a “worrisome 
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feature”, while MPD diameters ≥ 10 mm are considered “high-risk 
stigmata”. However, the MPD in MD-IPMN can be dilated without 
neoplastic involvement, due to mucin, protein plugs, or focal pan-
creatitis.13 Intralesional solid components can be observed, with 
calcification occurring in about 11% of these patients.14 Dystro-
phic calcifications can be seen in the mucous material in dilated 
A B C
Fig. 1. Branch duct type intraductal papillary mucinous neoplasm (IPMN) in a 60-year-old female. Contrast-enhanced computed tomography image (A) and T2-
weighted magnetic resonance imaging (MRI) (B) show a small cystic lesion (arrows) in the pancreas head. A communication (arrowhead) between the cystic lesion 
and the main pancreatic duct is suspected on T2-weighted MRI. (C) Magnetic resonance cholangiopancreatography image demonstrates a communication (arrowhead) 
between the cystic lesion and the main pancreatic duct, suggesting a diagnosis of branch duct type IPMN.
A B
Fig. 2. Main duct type intraductal papillary mucinous neoplasm (IPMN) in a 68-year-old male. (A) Contrast-enhanced computed tomography image shows marked 
dilatation of the main pancreatic duct (arrow) and several enhanced mural nodules (arrowheads) within the dilated main pancreatic duct. (B) Magnetic resonance 
cholangiopancreatography image shows the dilated and tortuous main pancreatic duct, suggesting main duct type IPMN.
A B C
Fig. 3. Combined type intraductal papillary mucinous neoplasm in a 74-year-old male. (A, B) Contrast-enhanced computed tomography images demonstrate lobu-
lated cystic lesions (arrows) in the pancreas head and the dilated main pancreatic duct. Multifocal enhanced mural nodules (arrowheads) are observed within the 
cystic lesion and the dilated main pancreatic duct. (C) Magnetic resonance cholangiopancreatography image shows large lobulated cystic lesions (arrowheads) con-
necting to the tortuous, dilated main pancreatic duct (arrow).
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MPDs.15 The pancreas may appear enlarged and show signs of 
pancreatitis, or may be atrophic. Endoscopic retrograde cholan-
giopancreatography can show filling defects, representing tumors 
or inspissated mucus, within the dilated duct.15 
Combined or mixed IPMN involves both the MPD and its BDs, 
with CT and MRI simultaneously showing findings of MD-IPMNs 
and BD-IPMNs (Fig. 3). The biologic characteristics of mixed 
IPMN may be similar to those of MD-IPMN.16
Features Suggestive of Malignant IPMN
One of the most important issues regarding IPMN has been 
the ability to predict malignancy. As described by the 2010 World 
Health Organization classification system,17 IPMNs can be cat-
egorized into four subtypes: low-grade dysplasia, intermediate-
grade dysplasia, high-grade dysplasia, and invasive carcinoma 
associated with IPMN. In most studies, malignant IPMN is defined 
as high-grade dysplasia and invasive carcinoma, inasmuch as 
surgical resection has been recommended for both.7,18 The imag-
ing features suggestive of malignant IPMN of the pancreas are 
summarized in Table 1. 
Table 1 Imaging Features Suggestive of Malignant IPMN of the Pancreas
Imaging features Description
The 2012 guideline
High-risk stigmata Worrisome feature
Presence of mural nodule/ 
solid component






Large size of mural nodule/ 
solid mass
A large size of mural nodule/solid mass is associated with  
malignancy (threshold nodule size, 5–10 mm).
Involvement of MPD Main duct type or mixed type IPMN has much higher malignant 
potential than BD-IPMN.
Large size of MPD diameter Marked MPD dilatation is associated with malignancy. MPD ≥ 10 mm MPD of 5–9 mm
Size of cystic lesion The cystic size > 3 cm have been reported a malignant feature  
in BD-IPMN.
Included
Thick septa or cystic wall Thick septa or cystic wall is associated with malignancy. Included
Lymphadenopathy The definition and significance of lymphadenopathy remain unclear. Included
Abrupt MPD change with  
distal pancreatic atrophy
The significance of abrupt MPD change with distal pancreatic  
atrophy remains unclear.
Included
Biliary obstruction Biliary dilatation is associated with malignancy of cystic lesion in 
the pancreas head.
Obstructive jaundice
Invasion of vascular or  
adjacent structures
Invasion of vascular or adjacent structures is associated with  
malignancy.
Intralesional calcification Intralesional calcification has been reported to be a malignant  
predictor, but controversy exists.
IPMN, intraductal papillary mucinous neoplasm; MPD, main pancreatic duct; BD-IPMN, branch duct type IPMN.
A B
Fig. 4. Main duct type intraductal papillary mucinous neoplasm (IPMN) with high-risk stigmata (enhanced solid component and main pancreatic duct diameter ≥10 
mm) in a 73-year-old male. (A, B) Contrast-enhanced computed tomography images show a diffusely dilated main pancreatic duct (arrow) with a diameter up to 23 
mm and several enhanced solid mural nodules (arrowheads) within the dilated main pancreatic duct. The pathologic diagnosis was main duct type IPMN with as-
sociated invasive carcinoma.
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The 2012 international consensus guidelines
Recently, the working group of the International Associa-
tion of Pancreatology updated international consensus guidelines 
for the management of IPMNs and mucinous cystic neoplasms 
of the pancreas.7 These 2012 guidelines have classified “high-
risk stigmata” as enhanced solid component on CT or MRI along 
with an MPD diameter ≥ 10 mm (Fig. 4). “Worrisome features” 
include cysts ≥ 3 cm in diameter, thickened enhanced cyst walls, 
MPD diameters of 5–9 mm, non-enhanced mural nodules, abrupt 
Fig. 5. Branch duct type intraductal papillary mucinous neoplasm (IPMN) 
with a worrisome feature (cyst ≥ 3 cm in diameter) in a 63-year-old female. 
Contrast-enhanced computed tomography image shows a 4-cm lobulated cys-
tic lesion (arrow) in the pancreas head, which was pathologically confirmed as 
branch duct type IPMN with low-grade dysplasia.
Fig. 6. Branch duct type intraductal papillary mucinous neoplasm (IPMN) with 
a worrisome feature (thickened enhanced septum) in a 73-year-old female. 
Contrast-enhanced computed tomography image demonstrates a 2.5-cm cystic 
lesion with a thickened enhanced septum (arrow) in the pancreas tail, which was 
pathologically confirmed as branch duct type IPMN with low-grade dysplasia.
A B C
Fig. 7. Combined type intraductal papillary mucinous neoplasm (IPMN) with two worrisome features (main pancreatic duct 5–9 mm in diameter and lymphadenopa-
thy) in a 73-year-old male. (A-C) Contrast-enhanced computed tomography images demonstrate mild dilatation of the main pancreatic duct (A, arrow), measuring 
6 mm in diameter, and several cystic lesions (B, arrow) in the pancreas tail. Several borderline-sized lymph nodes (arrowheads) are observed in the hepatoduodenal 
ligament (A), peripancreatic area (B), and gastrohepatic ligament (C). The pathologic diagnosis was combined type IPMN with intermediate-grade dysplasia.
A B C
Fig. 8. Main duct type intraductal papillary mucinous neoplasm (IPMN) with a worrisome feature (abrupt change in main pancreatic duct caliber with distal pancre-
atic atrophy) in a 75-year-old female. (A, B) Contrast-enhanced computed tomography images show abrupt main pancreatic duct dilatation (arrows) in the pancreas 
tail with distal pancreatic atrophy (arrowhead). (C) Magnetic resonance cholangiopancreatography image also shows abrupt changes in main pancreatic duct diam-
eter in the pancreas tail. The pathologic diagnosis was main duct type IPMN with intermediate-grade dysplasia.
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change in the MPD caliber with distal pancreatic atrophy, and 
lymphadenopathy (Fig. 5–8). Resection is recommended in all sur-
gically fit patients with MD-IPMN and BD-IPMN having “high-risk 
stigmata”. By contrast, further evaluation by endoscopic ultraso-
nography (EUS) is recommended for BD-IPMNs with “worrisome 
features”, thereby stratifying the risk of malignancy.
Several studies have evaluated the clinical utility of these 
2012 guidelines.10,19,20 In a recent systematic review validating the 
2012 guidelines in 1,382 surgically resected patients,20 a pooled 
analysis showed that there were 362 (36.2%) malignant IPMNs 
in 1,000 patients with high risk and worrisome features, and 342 
(89.5%) benign IPMNs in 382 patients without high risk/worri-
some features. The positive predictive values (PPVs) of the high 
risk and worrisome risk groups were 65.8% (104/158) and 28.7% 
(75/261), respectively.20 In a recent study by our group,10 60 pa-
tients with surgically confirmed BD-IPMNs and 98 with confirmed 
MD-IPMNs were further evaluated by both CT and MRI. For BD-
IPMNs, the sensitivity and specificity of overall significant find-
ings on univariate analyses (i.e., mural nodule, thick septa, and 
MPD size ≥ 5 mm) for predicting malignancy on both CT and MRI 
were 87.5% and 75.0%, respectively. For MD-IPMNs, the sensitiv-
ity and specificity of overall significant findings (i.e., presence of 
mural nodules and enhancement, lymphadenopathy, and mural 
nodule size > 7 or 8 mm) were 72.7% and 75.9%, respectively, 
on CT, and 77.3% and 81.5%, respectively, on MRI.10 Using the 
criterion of the presence of at least one worrisome feature or high 
risk stigmata in BD-IPMN, CT had a PPV and negative predictive 
value (NPV) of 23.3% and 96.7%, respectively, whereas MRI had 
a PPV and NPV of 20.0% and 96.0%, respectively. For MD-IPMN, 
the PPV and NPV were 47.7% and 80.0%, respectively, for CT, 
and 45.7% and 66.7%, respectively, for MRI. The PPVs of high 
risk stigmata or worrisome features in this study were relatively 
low, consistent with the results of the recent systematic review.20 
Another study, in which 98 patients with pathologically con-
firmed IPMN were evaluated using MRI and MRCP, found that the 
sensitivity and specificity of the 2012 guidelines by three readers 
were 79%–90% and 24%–80%, respectively.19
Presence of solid mural nodules
The presence of solid mural nodules is one of the most im-
portant predictors of malignancy of IPMNs (Fig. 4).10–12,21,22 In a 
recent meta-analysis, the presence of mural nodules had the high-
est diagnostic odds ratio (OR) of 6.0 for malignant BD-IPMNs.12 
Another meta-analysis also reported that the presence of mural 
nodules had an OR of 9.3 for malignancy of IPMNs.23 The 2012 
guidelines differentiated mural nodules by the presence or absence 
of enhancement.7 Enhanced mural nodules are defined as “high-
risk stigmata”, while non-enhanced mural nodules are regarded 
as “worrisome features”. Our recent study found that 52 among 
53 mural nodules in pancreatic IPMNs were enhanced.10 Although 
mural nodules attach to the cystic wall and may be located in 
non-dependent positions,24,25 differentiating non-enhanced mural 
nodules from mucin components or internal debris may some-
times be difficult. Additional studies are needed to determine the 
significance of non-enhanced mural nodules.
Size of mural nodules
Large size of mural nodules has also been reported to be as-
sociated with malignant IPMN. The cutoff value of mural nodule 
size for predicting malignancy has been found to range from 
5 mm to 10 mm. Mural nodule size > 7 mm on EUS showed a 
sensitivity of 74.3% and a specificity of 72.7% for predicting ma-
lignancy.26 Another study showed that mural nodules > 5 mm in 
BD-IPMN on EUS were one of the most important factors predict-
ing malignancy.27 In our previous study using preoperative cross-
sectional imaging, cutoff values of 8 mm on CT and 7 mm on 
MRI enhanced diagnostic performance, especially the specificity 
for diagnosis of malignant IPMN.10
Dilatation of the main pancreatic duct
The 2012 guidelines define MPD sizes of ≥ 10 mm and 5–9 
mm as “high-risk stigmata” and “worrisome features”, respec-
tively (Fig. 4, 7).7 Many studies have reported that marked dilata-
tion of the MPD is associated with malignant IPMN.12,22,23,28,29 A 
recent meta-analysis assessing characteristics of BD-IPMN as-
sociated with malignancy30,31 reported that MPD > 6 mm or 5–9 
mm showed the second highest diagnostic performance after the 
presence of a mural nodule. By contrast, MPD size criteria of 10 
mm have been a source of controversy. MPD > 10 mm was not a 
significant predictor of malignancy in both MD- and BD-IPMNs 
in our previous study.10 Other studies also demonstrated that MPD 
> 10 mm was not significantly different between benign and ma-
lignant IPMNs.18,32 The significance of MPD size in MD-IPMN is 
also questionable.33,34 A recent study suggested that MPD size did 
not correlate with malignant potential in MD-IPMN because MD-
IPMNs with MPD < 5 mm still had substantial malignant poten-
tial.34
Large cyst size (> 3 cm)
Although the 2006 guidelines suggested that cyst size > 3 
cm is a malignant feature in BD-IPMNs,3,23,29,35,36 its significance 
remains unclear (Fig. 5). Several recent studies found no signifi-
cant differences in malignancy between cysts < 3 cm and ≥ 3 
cm.10,11,19,27,37 A meta-analysis of patients with BD-IPMN and the 
2012 guidelines suggested that BD-IPMNs > 3 cm without other 
features associated with malignancy may not indicate the need 
for immediate surgical resection, particularly in elderly patients.12 
Other findings
A meta-analysis found that thick septa or cystic walls were 
significantly associated with malignant BD-IPMN (Fig. 6).12 How-
ever, its absolute diagnostic value was fairly weak, with a pooled 
sensitivity and specificity of 58% and 60%, respectively.12 Our 
previous study showed that the presence of thick septa was a 
significant predictor for malignancy in BD-IPMN on univariate 
analysis, but not on multivariable analysis, and was not a signifi-
cant predictor of malignancy in MD-IPMN.10 The vagueness of 
this criterion suggests the need for more accurate definition and 
further studies evaluating its diagnostic performance.
The significance of lymphadenopathy remains unclear (Fig. 
7).10,18,21 Our previous study found that lymphadenopathy was a 
significant predictor for malignant MD-IPMN, with high specific-
ity (92.6% for CT and 96.3% for MRI) and relatively low sensitiv-
ity (34.1% for CT and 29.6% for MRI).10 In another study involv-
ing 350 BD-IPMNs, lymphadenopathy was significant only in 
univariate analysis, with a sensitivity of 7.2% and a specificity of 
99.6%, but not in multivariable analysis.21 By contrast, a study of 
114 mucinous cystic lesions of the pancreas found that lymph-
adenopathy did not differ significantly between benign and ma-
lignant lesions.18 One possible explanation for these discrepancies 
may be the lack of an accurate definition of lymphadenopathy in 
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IPMN.
The 2012 guidelines define an abrupt change in MPD diam-
eter with distal pancreatic atrophy as a worrisome feature (Fig. 8).7 
Distal pancreatic atrophy is defined as a ratio of MPD diameter to 
the width of the pancreatic parenchyma at the same level greater 
than 0.5.10,38 However, studies found that this finding was not a 
significant predictor of malignant IPMN.10,18,21
Other reported imaging features of malignant IPMN which 
were not suggested in the 2012 guidelines include solid mass 
invading adjacent structure, presence of vascular invasion or 
distant metastasis.8,28 Biliary dilatation or CBD obstruction can be 
caused by direct tumor invasion or retention of mucin.28 Many 
studies demonstrated significant correlation between biliary dila-
tation and malignant IPMN.14,39,40 Obstructive jaundice, which is 
the clinical presentation of biliary obstruction, is one of “high-
risk stigmata” in the 2012 guidelines. Intralesional or intraductal 
calcifications were reported to be associated with malignancy in 
several studies, and showed sensitivity of 18%–33% and specific-
ity of 77%–87%.14,22 However, another study did not find signifi-
cant difference in the presence of calcification between benign 
and malignant IPMNs.40 Regarding location of the cystic lesion, 
majority of studies showed no significant correlation between 
location of the lesion and malignant potential,41–43 although a few 
studies reported that malignant IPMNs were most frequent in the 
pancreas head.29,44 
Diagnostic Performance of CT and MRI
The 2012 guidelines recommend either CT or MRI with MRCP 
for evaluation of pancreatic cystic lesions larger than 1 cm.7 In 
our previous study involving 158 patients with both CT and MRI, 
CT and MRI with MRCP showed comparable good performance 
for diagnosing malignancy in both BD-IPMN and MD-IPMN, 
with both CT and MRI showing accuracies of 76.7%–78.3% for 
BD-IPMN, and these two modalities showing accuracies of 74.5% 
and 79.6%, respectively, for MD-IPMN.10 A previous study with 
25 IPMNs also demonstrated that CT and MRCP showed similar 
sensitivity and specificity for evaluating mural nodules, MPD > 
10 mm, thick septa, and calcifications.45 However, a recent study 
with 60 IPMNs showed that MRI was slightly superior to CT in 
diagnosing malignancy, with accuracies of 92% and 86%, respec-
tively, although the difference was not statistically significant.32 
Moreover, MRI showed a trend towards significance for predicting 
malignancy with increasing size of mural nodules, while CT did 
not show such correlation.32 Technological improvements in both 
CT and MRI, including thinner slice thicknesses and higher tem-
poral and spatial resolution, may improve their diagnostic perfor-
mance over time.
Conclusion
In summary, the presence of solid mural nodules is thought 
to be the most important predictor of malignancy in IPMN. Over-
all findings using the 2012 guidelines demonstrated acceptable 
sensitivity and specificity. However, these guidelines resulted in a 
relatively low PPV, suggesting the need for further investigation 
and modification. In addition, several worrisome features, includ-
ing thickened septa or cystic walls, lymphadenopathy, and distal 
pancreatic atrophy, should be defined more precisely. Both CT 
and MRI have shown good diagnostic performance for predicting 
malignant IPMN, and their ability may be further improved by 
further technological developments.
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